Arbutus Biopharma (ABUS) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Several other analysts have also issued reports on the company. ValuEngine upgraded Arbutus Biopharma from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Chardan Capital restated a buy rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Zacks Investment Research lowered Arbutus Biopharma from a hold rating to a sell rating in a research note on Thursday, January 18th. Finally, B. Riley assumed coverage on Arbutus Biopharma in a research note on Friday, January 5th. They issued a buy rating and a $10.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $12.50.

Shares of Arbutus Biopharma (NASDAQ ABUS) traded up $0.20 on Friday, hitting $5.80. The company’s stock had a trading volume of 179,440 shares, compared to its average volume of 140,616. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03. Arbutus Biopharma has a 52-week low of $2.55 and a 52-week high of $8.25.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP grew its position in shares of Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares in the last quarter. BlackRock Inc. grew its position in shares of Arbutus Biopharma by 7,615.3% in the fourth quarter. BlackRock Inc. now owns 751,314 shares of the biopharmaceutical company’s stock valued at $3,794,000 after purchasing an additional 741,576 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Arbutus Biopharma by 150.7% in the fourth quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock valued at $2,033,000 after purchasing an additional 241,963 shares in the last quarter. Hudson Bay Capital Management LP grew its position in shares of Arbutus Biopharma by 239.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,020,000 after purchasing an additional 282,000 shares in the last quarter. Finally, K2 Principal Fund L.P. grew its position in shares of Arbutus Biopharma by 4.5% in the fourth quarter. K2 Principal Fund L.P. now owns 261,326 shares of the biopharmaceutical company’s stock valued at $1,320,000 after purchasing an additional 11,311 shares in the last quarter. Institutional investors own 62.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/03/11/arbutus-biopharma-abus-lifted-to-hold-at-bidaskclub.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply